The ZEUS Dual Antigen Difference. Does your SARS-CoV-2 antibody test detect antibodies to both nucleocapsid protein and spike S1-RBD protein?
The Dual Antigen Difference
Does your antibody test detect antibodies to both the nucleocapsid protein and the S1-RBD (spike protein) of SARS-CoV-2?
Try a ZEUS SARS-CoV-2 IgG Test System evaluation kit. Contact your sales representative today.
As the COVID-19 pandemic continues to surge in 2021 and vaccines are being rolled out, interest in SARS-CoV-2 antibody testing is increasing. Individuals want to know if they have been exposed to the SARS-CoV-2 virus and, if following vaccination, they have generated antibodies. Doctors want to get this information for their patients and researchers want to better understand the antibody response.
For anyone interested in seeing the antibody response following vaccination, understanding if the test being used is capable of detecting the appropriate immune response is important.
The ZEUS ELISA SARS-CoV-2 Test Systems are designed to detect antibodies against both the Nucleocapsid protein and the Spike protein S1-RBD and is optimized for superior sensitivity and specificity. What is the target of the SARS-CoV-2 antibody test you use today?
See firsthand the performance of utilizing two antigens for both S1-RBD and nucleoprotein. Contact firstname.lastname@example.org for an evaluation kit for the ZEUS ELISA SARS-CoV-2 IgG Test System.
The ZEUS ELISA SARS-CoV-2 IgG Test System has FDA Emergency Use Authorization and follows ZEUS universal ELISA assay protocol for easy incorporation with your existing test menu. It can be used manually or with the Dynex Agility Automated ELISA System. The Agility offers high throughput and takes advantage of the SmartKit™ Gold packaging, providing the ability to fully automate the procedure from sample to result in a throughput meeting all laboratory requirements.
Test with Confidence. Test with ZEUS.
The Dual Antigen Difference: Specificity Matters
Schematic labelled diagram of Coronavirus (SARS-CoV)2
S1-RBD: The surface glycoprotein of the virus, termed the spike (S) protein, mediates attachment of the virus to human cells via its receptor‐binding domain (RBD)1 and mediates fusion of viral and cellular membranes. Antibodies binding to the spike protein, and especially to the RBD domain, can neutralize SARS-CoV-2.
N-Protein: The nucleocapsid protein (N-protein) is the most abundant protein in coronavirus. The N-protein is a highly immunogenic phosphoprotein, and it is normally very conserved. The N protein of coronavirus is often used as a marker in diagnostic assays.
During virion assembly, N protein binds to viral RNA and leads to formation of the helical nucleocapsid. The abundance and high hydrophilicity of N protein are supposed to contribute to potent immunity after coronavirus infection.
ZEUS’s dual antigen approach is unique as most available tests are limited to one or the other. By detecting antibodies directed against both the highly immunogenic N-protein and the neutralizing S1-RBD our assay is optimized for superior sensitivity and specificity.
Learn more at zeuscovid.com. We are here to help with your transition!
The ZEUS Scientific Family
1 Wrapp et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260-1263 (2020).
2 Taken from Peiris et al. Severe acute respiratory syndrome. Nature Medicine Vol 10 (12) (2004).
FDA EUA Disclaimer: This test has been authorized only for the presence of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has not been FDA cleared or approved; This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Terms and conditions: For new adopters of our ELISA SARS-CoV-2 IgG Test System only, discounted price ends February 26, 2021.